VALN Valneva
- 8.695
- +0.685+8.55%
Valneva News
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)
Valneva's Chikungunya Vaccine Shows Promise in Adolescents
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for Its Single-Shot Chikungunya Vaccine
Results Intended to Support Filing for Potential Label Extension for Use in Adolescents Saint-Herblain (France), May 13, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Denali Therapeutics (DNLI) and Armata Pharmaceuticals (ARMP)
Valneva Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Valneva Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : Valneva (VALN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $26.00.
HC Wainwright & Co. : Valneva (VALN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $26.00.
Valneva SE Boasts Strong Q1 2024 Performance
Valneva | 6-K: Report of foreign private issuer (related to financial reporting)
Valneva Turns To Q1 Profit On PRV Sale Gain; Backs Annual Revenue Guidance
Valneva For 2024 Expects Total Revenues Of €170M-€190M And R&D Investments Between €60M-€75M
2024 financial guidance confirmedExpected total revenues between €170 million and €190 million, including: €160 million to €180 million of sales driven by growth of Valneva's proprietary products Expe
Valneva Q1 Revenue €32.8M Down From €33.5M YoY, Net Profit €58.9M Up From Net Loss €18.1M YoY
Net Profit of €58.9 million, reflecting PRV sale
Declaration of Shares and Voting Rights April 30, 2024 - VALNEVA SE
Declaration of Voting Rights - Valneva SE, March 2024
VALNEVA Declaration of shares and voting rights March 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue A
Buy Rating on Valneva Supported by Promising Vaccine Developments and Solid Revenue Projections
Valneva SE Files Key Financial Documents for 2023
Valneva Initiates Phase 1 Study Of Zika Virus Vaccine Candidate
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
Saint-Herblain (France), March 25, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French
Valneva Is Maintained at Buy by Guggenheim
Valneva Is Maintained at Buy by Guggenheim
Valneva Price Target Cut to $17.00/Share From $18.00 by Guggenheim
Valneva Price Target Cut to $17.00/Share From $18.00 by Guggenheim
What Analysts Are Saying About Valneva Stock
Valneva (NASDAQ:VALN) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below provides a concise overview of recent ratings by
Analysis
Price Target
No Data
